From: Multiple gene aberrations and breast cancer: lessons from super-responders
Patient No. | 1 | 2 | 3 |
---|---|---|---|
Age at Treatment (years) | 38 | 48 | 44 |
Date of Diagnosis | August 2009 | September 2007 | September 2010 |
Date of Biopsy | August 2009 | September 2007 | August 2010 |
Histology | Ductal | Ductal | Ductal |
ER Status | 90Â % Positive | 95Â % Positive | 95Â % Positive |
PR Status | 60Â % Positive | 80Â % Positive | Negative |
HER2/neu Status | Negative (FISH) | Negative (FISH) | Negative (IHC) |
Prior Treatment in Metastatic Setting | Paclitaxel (3Â months) 5-fluorouracil, doxorubicin, cyclophosphamide (1Â month) Tamoxifen (3Â months) Capacitabine ( 3Â months) | Tamoxifen (2Â months) Paclitaxel, bevacizumaba Vinorelbinea Fulvestrant (3Â months) Ixabepilonea Docetaxel (9Â months) Docetaxel, doxorubicin, cyclophosphamide (3Â months) | Tamoxifen, zoledronic acid (6Â months) Letrozole (4Â months) |
Prior Treatment with Aromatase Inhibitor in Metastatic Setting (Duration) | No | No | Yes (4Â months) |
Molecular alterations (Please reference Additional file 1: Table S1) | Â | Â | Â |
Progression Free Survival (months) | 11 | 14 | 9+ |
Best Response (%) | −56 % | −38 % | −100 % |